<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478033</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZX10202101-002</org_study_id>
    <nct_id>NCT03478033</nct_id>
  </id_info>
  <brief_title>Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis</brief_title>
  <acronym>RRHT</acronym>
  <official_title>The Efficacy and Safety Evaluation of Standardized Treatment Included Rifampicin or Rifabutin in HIV/AIDs Patients Combined With Pulmonary Tuberculosis. A Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Guangxi Zhuang Autonomous Region Longtan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth People’s Hospital of Nanning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Provincial Infectious Disease Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Public Health Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compared the efficacy and safety of rifampicin and rifabutin which included in the
      standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary
      tuberculosis, a multi-center, prospective cohort will be established. Antiviral efficacy and
      drug drug interaction will be investigated in order to provide optimized treatment for
      HIV/AIDs with tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two hundreds and thirty participants will be randomly assigned to receive an
      anti--tuberculosis treatment include rifampicin or rifabutin for two months of intensive
      therapy. Isoniazid and rifampicin (or rifabutin) will be continued to use for four months of
      consolidation therapy. A total of followed up period will be 12 months.

      The antiretroviral therapy（ART） include:

      Tenofovir disoproxil fumarate 300mg/d +Lamivudine 300mg/d+ Efavirenz 600mg/d; or Zidovudine
      300mg bid +Lamivudine 300mg/d +Efavirenz 600mg/d.

      ART will be started after 2 weeks of anti-tuberculosis.

      The follow-up visits include 2th, 4th, 6th, 8th, 12th,16th, 20th, 24th, 32th, 36th, 40th,
      44th and 48th week. sputum smear, sputum culture, chest X-ray, CD4 Lymphocyte counts,HIV
      viral load and adverse event will be tested and recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participates are assigned to one of two groups in parallel for the duration of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of sputum negative conversion</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>The rate of the patients whose mycobacterium tuberculosis cannot be detected in sputum smear or bacteria culture.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Case fatality rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of deaths during follow-up caused by HIV/AIDS and TB / the number of patients with HIV/AIDs and TB enrolled in this study * 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment completion status</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of patients who complete the whole anti-tuberculous treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HIV viral load less than the detection limit</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The percentage of HIV viral load less than the detection limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>12 months</time_frame>
    <description>The number and severity of adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of sputum negative conversion</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>The time of sputum negative conversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest CT scans improvement</measure>
    <time_frame>2~24 weeks</time_frame>
    <description>Chest CT showed tuberculosis lesion absorption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>Rifampicin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.
isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W＜50kg)；1.0 g/d（W≥50kg）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifabutin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.
isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W＜50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W＜50kg)；1.0 g/d（W≥50kg）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Rifampicin capsules, 150mg</description>
    <arm_group_label>Rifampicin group</arm_group_label>
    <other_name>Rifampicin/INH/EMB/PZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin capsules, 150mg</description>
    <arm_group_label>Rifabutin group</arm_group_label>
    <other_name>Rifabutin/INH/EMB/PZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18－65 years old;

          2. No limited to gender;

          3. If anti-HIV-1 positive samples are detected by an initial test based on the ELISA
             method, they should be confirmed by western blot;

          4. The patients who are diagnosed with pulmonary TB (mycobacterium tuberculosis of sputum
             smear or culture was positive) but had never be treated;

          5. Sign informed consent form voluntarily, and guarantee to attend follow-up visits;

          6. Do not have plan to remove from the current experimental site during the trial
             process;

          7. The patients do not receive any antiretroviral treatment before;

          8. The overall situation of the patient should not affect the assessment and completion
             of the trial.

        Exclusion Criteria:

          1. Patients with acute infection;

          2. During the screening period，patients with combined opportunistic infections and
             instability (National HIV/AIDS treatment guidelines) except for tuberculosis, or
             combined malignancy;

          3. During the screening period，hemachrome &lt; 6 g/dl, leukocyte &lt; 2000 /µl, neutrophils &lt;
             1000 /µl, platelet count &lt; 75000 /µl, blood amylase is greater than two times the
             upper limit of normal, Scr is greater than1.5 times the upper limit of normal,
             AST/ALT/AKP is greater than two times the upper limit of normal, TBIL is greater than
             two times the upper limit of normal, serum CK is greater than two times the upper
             limit of normal;

          4. Now suffering from acute or chronic pancreatitis;

          5. Now suffering from peripheral neuritis;

          6. Pregnant and lactating women;

          7. Patients with severe mental and neurological diseases;

          8. Drug users；

          9. Patients with history of heavy drinking and cannot be terminated;

         10. Serious gastrointestinal ulcers；

         11. Atherosclerosis affects the arteries in the heart, brain or kidneys；

         12. Non-Chinese nationality；

         13. Now suffering from myopathy；

         14. Patients with previously treated tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, PhD，MD</last_name>
    <phone>86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingzhong Shen, PhD，MD</last_name>
      <phone>86-021-37990333</phone>
      <phone_ext>3222</phone_ext>
      <email>027465@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>vice director</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>AIDS</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Rifabutin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

